Comparative Pharmacology
Head-to-head clinical analysis: CRYSVITA versus LEMTRADA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSVITA versus LEMTRADA.
CRYSVITA vs LEMTRADA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
None Documented
None Documented
16.4 days (terminal elimination half-life); supports monthly subcutaneous dosing.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Renal (minimal, as intact antibody); catabolized into small peptides and amino acids; no biliary/fecal elimination of intact drug.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody